(Q35963932)

11 August 2017

Lung function in adult patients with cystic fibrosis after using the eFlow rapid for one year (English)

1 reference

11 August 2017

0 references

Susanne Naehrig

1

1 reference

11 August 2017

S Lang

2

1 reference

11 August 2017

H Schiffl

3

1 reference

11 August 2017

R M Huber

4

1 reference

11 August 2017

R Fischer

5

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 February 2011

1 reference

European Journal of Medical Research

11 August 2017

1 reference

11 August 2017

16

1 reference

11 August 2017

2

1 reference

11 August 2017

63-66

1 reference

https://scigraph.springernature.com/pub.10.1186/2047-783x-16-2-63

11 August 2017

0 references

cites work

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3353423

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis

2 October 2017

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F2047-783X-16-2-63

A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability.

21 January 2018

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3353423

24 September 2018

Adult cystic fibrosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21463983

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/2047-783X-16-2-63

1 reference

Dimensions Publication ID

11 August 2017

0 references

1 reference

11 August 2017

1 reference